FDA Clinical Hold Squeezes Investors
Shares of Achillion plunged 25% after the FDA stuck a clinical hold on its key next-gen hepatitis C drug sovaprevir. There has been a history of clinical holds for interferon-free treatment components, but Achillion's problems are different from past struggles seen by competitors.
In this video, health-care analyst David Williamson discusses why today's sell-off may be overdone, but cautions investors to look at the bigger picture surrounding this fledgling small cap.
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article FDA Clinical Hold Squeezes Investors originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson. Follow David on Twitter @MotleyDavid. The Motley Fool recommends Gilead Sciences. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.